IBB Up 51% Yearly; Eli Lilly (LLY) Completes Four Acquisitions
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowThe iShares Biotechnology ETF (IBB) has risen 51% over the last year and is up 16.06% year to date, compared to a 9.22% gain for the S&P 500. Eli Lilly (LLY) has announced four acquisitions in Q1 2026 and reported Q1 revenues of $19.80 billion, a 55.5% increase year over year. The company's Mounjaro revenue reached $8.66 billion, a 125% growth. Cramer expects an influx of deals in the biotech sector following changes in FDA leadership, making biotech an attractive sector for investors given current market conditions.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
- Premarket Moves: Key Stocks Including AAPL, PEP, CRM, and LLY
- Lilly (LLY) to Present Alzheimer's Research at London Conference
- IHE vs PJP: Key ETF Metrics Include Expense Ratios and Dividends
- Eli Lilly (LLY) selected for FDA's PreCheck pilot program
- Tesla (TSLA) Market Moves Amid Dow Jones Futures Analysis
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
